Recently, CD44 has also been found to be preferentially loaded into cancer-derived exosomes and has been implicated in driving chemoresistance in a model of doxorubicin-treated breast cancer (Wang et al., 2020). The gene discussed is CD44; the disease is breast carcinoma.